Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Feb;25(2):144-50.
doi: 10.1016/j.jnutbio.2013.09.013. Epub 2013 Nov 6.

Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial

Somlak Chuengsamarn  1 , Suthee Rattanamongkolgul  2 , Benjaluck Phonrat  3 , Rungsunn Tungtrongchitr  4 , Siwanon Jirawatnotai  5
Affiliations
Free article
Randomized Controlled Trial

Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial

Somlak Chuengsamarn et al. J Nutr Biochem. .
Free article
Favorites

Abstract

Curcumin is a phytocompound found in the root of turmeric, a common herbal ingredient in many Asian cuisines. The compound contains anti-inflammatory activity, which is mediated through an up-regulation of adiponectin and reduction of leptin. Consumption of curcumin was shown to prevent some deteriorative conditions caused by inflammation, such as ulcerative colitis, rheumatoid arthritis and esophagitis, and so on. Inflammation-associated cardiovascular conditions such as atherosclerosis are common in diabetes patients. The anti-inflammation effect of curcumin might be beneficial to prevent such condition in these patients. We aim to evaluate an antiatherosclerosis effect of curcumin in diabetes patients. Effects of curcumin on risk factors for atherosclerosis were investigated in a 6-month randomized, double-blinded and placebo-controlled clinical trial that included subjects diagnosed with type 2 diabetes. An atherosclerosis parameter, the pulse wave velocity, and other metabolic parameters in patients treated with placebo and curcumin were compared. Our results showed that curcumin intervention significantly reduced pulse wave velocity, increased level of serum adiponectin and decreased level of leptin. These results are associated with reduced levels of homeostasis model assessment-insulin resistance, triglyceride, uric acid, visceral fat and total body fat. In summary, a 6-month curcumin intervention in type 2 diabetic population lowered the atherogenic risks. In addition, the extract helped to improve relevant metabolic profiles in this high-risk population.

Trial registration: ClinicalTrials.gov NCT01052597.

Keywords: Abdominal obesity (visceral fat and total body fat); Atherogenic risk; Curcuminoid extract; Insulin resistance; Pulse wave velocity (PWV); Type 2 diabetes.

Similar articles

See all similar articles

Cited by 44 articles

See all "Cited by" articles

Publication types

Associated data

Feedback